{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Expert Roundtable Discussion: Optimizing the Management of SMA in Clinical Practice
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
To access this FREE activity, please login (or register first in a new tab). After login, click on the blue +Cart button and enter the Coupon Code: SMAFREEThe field of spinal muscular atrophy (SMA) is rapidly evolving as new treatments become available, newborn screening programs are introduced, and we gain a better understanding of how best to provide the necessary multidisciplinary care. Watch this 1-hour webcast for practical, up-to-date insights from leading experts in SMA. Dr. Claudia Chiriboga, Dr. Richard Finkel, and Dr. Julie Parsons discuss the latest understanding of SMA management, including a look at likely future developments in the field. Target Audience This activity is designed to meet the educational needs of pediatric and adult neurologists, neuromuscular disease specialists, physical therapists, and other healthcare professionals with an interest in SMA.
Learning Objectives
After completing this continuing education activity you will be able to:
- Implement the optimal process for early diagnosis, and make a case for early treatment initiation
- Explain the importance of multidisciplinary care in SMA, and assess challenges regarding local implementation and coordination
- Outline and examine the approach to intrathecal drug administration for different types of patient
- Evaluate the benefits of treatment for patients with later-onset SMA, and discuss individual treatment goals
Disclosures
Dr. Chiriboga has disclosed that she was/is a consultant/advisor AveXis, Inc, Biogen, and Roche; was/is a recipient of grant/research funds from AveXis, Inc, Biogen, and Roche; and she was/is a member of the speakers' bureau at Biogen
Dr. Parsons has disclosed that she was/is a consultant/advisor AveXis, Inc and Biogen; and was/is a recipient of grant/research funds from Biogen, Cytokinetics, and Scholar Rock, Inc. Dr. Finkel has disclosed that he was/is a consultant/advisor AveXis, Inc., Biogen, and Roche; and was/is a recipient of grant/research funds from AveXis, Inc., Biogen, and Roche. Non-Faculty All planners in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interest in, any commercial organizations pertaining to this educational activity. Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Lippincott CME Institute and Ology Medical Education do not recommend the use of any agent outside of the labeled indications.Financial Support
This activity has been supported by an independent educational grant from Biogen MA Inc. Method of Participation1. Site registration is required to begin this activity. Please click the blue "+Planner" button and follow the instructions to register.
2. Read the educational objectives, accreditation information, and faculty disclosures. 3. Take the pre-test. 4. Watch the webcast. 5. Take the post-test and complete the evaluation.
Price:
$100.00
Credits:
- ACCME 1.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Physician
Test Code: SMAWEB819
Published: September 2019
Expires: 1/1/2026
Sources:
Grant Supported
Required Passing Score: 4/5 (80%)